J.L. Myers

TL;DR: Many acute and chronic lung disorders with variable degrees of pulmonary inflammation and fibrosis are collectively referred to as interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases.

TL;DR: To better reflect the current state of knowledge and improve the feasibility of future research into its etiology and treatment, the working group proposes a new conceptual framework for acute respiratory deterioration in idiopathic pulmonary fibrosis and a revised definition and diagnostic criteria for acute exacerbation.

TL;DR: The most common diagnosis for exclusion was suspected chronic hypersensitivity pneumonitis (CSPP) and the most common adverse events were suspected acute exacerbations (AEx) and nonelective hospitalizations as mentioned in this paper.

TL;DR: A 66-year-old with biopsy-proven pulmonary and systemic LCH, whose pulmonary abnormalities responded dramatically to treatment with 2-chlorodeoxyadenosine (2-CdA), is described, and it is proposed that, in selected cases, 2-CDA should be considered in the management of pulmonary LCH.

TL;DR: A novel murine model shows consistent and reproducible allograft fibrogenesis in the context of single-lung transplantation and represents a major step forward in investigating mechanisms of chronic graft failure.